CA3022983C - Ophthalmic compositions comprising chlorhexidine and an anti-inflammatory agent - Google Patents
Ophthalmic compositions comprising chlorhexidine and an anti-inflammatory agent Download PDFInfo
- Publication number
- CA3022983C CA3022983C CA3022983A CA3022983A CA3022983C CA 3022983 C CA3022983 C CA 3022983C CA 3022983 A CA3022983 A CA 3022983A CA 3022983 A CA3022983 A CA 3022983A CA 3022983 C CA3022983 C CA 3022983C
- Authority
- CA
- Canada
- Prior art keywords
- ophthalmic composition
- chlorhexidine
- ophthalmic
- solvent
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332789P | 2016-05-06 | 2016-05-06 | |
| US62/332,789 | 2016-05-06 | ||
| US201662337571P | 2016-05-17 | 2016-05-17 | |
| US62/337,571 | 2016-05-17 | ||
| PCT/US2017/031211 WO2017192944A1 (en) | 2016-05-06 | 2017-05-05 | Ophthalmic compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3022983A1 CA3022983A1 (en) | 2017-11-09 |
| CA3022983C true CA3022983C (en) | 2024-05-07 |
Family
ID=58709627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3022983A Active CA3022983C (en) | 2016-05-06 | 2017-05-05 | Ophthalmic compositions comprising chlorhexidine and an anti-inflammatory agent |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10610499B2 (enExample) |
| EP (1) | EP3452093B1 (enExample) |
| JP (1) | JP6941157B2 (enExample) |
| CN (1) | CN109715215A (enExample) |
| AU (1) | AU2017261303B9 (enExample) |
| BR (1) | BR122024001664A2 (enExample) |
| CA (1) | CA3022983C (enExample) |
| DK (1) | DK3452093T3 (enExample) |
| TW (1) | TWI738774B (enExample) |
| WO (1) | WO2017192944A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10610499B2 (en) | 2016-05-06 | 2020-04-07 | SaCSh Corp. | Ophthalmic compositions |
| KR102340804B1 (ko) * | 2019-07-22 | 2021-12-17 | 주식회사 휴온스메디케어 | 클로르헥시딘 또는 이의 유도체를 포함하는 항균 지속성이 개선된 수용성 소독용 조성물 및 이를 포함하는 섬유형 소독제 |
| US20220409633A1 (en) * | 2019-12-03 | 2022-12-29 | Ntc S.R.L. | Composition comprising budesonide for ophthalmic use |
| US12357594B1 (en) | 2021-06-30 | 2025-07-15 | Sage Products, Llc | Antimicrobial solution for pre-operative preparation |
| US11951087B2 (en) * | 2021-07-27 | 2024-04-09 | Lanny Leo Johnson | Eye wash compositions and methods |
| WO2025176750A1 (en) | 2024-02-23 | 2025-08-28 | Heinrich-Heine-Universität Düsseldorf | Dual targeting in a new class of active ingredients |
| CN119792261B (zh) * | 2025-03-14 | 2025-07-11 | 华中科技大学同济医学院附属同济医院 | 治疗泌尿系感染的抗菌剂及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO59572A2 (enExample) | 1972-01-29 | 1976-03-15 | ||
| JP3781792B2 (ja) * | 1993-12-27 | 2006-05-31 | 千寿製薬株式会社 | ジフルプレドナート含有点眼用懸濁液剤 |
| AU684115B2 (en) * | 1993-12-27 | 1997-12-04 | Mitsubishi Chemical Corporation | Ophthalmic suspension containing diflupredonate |
| ATE215821T1 (de) * | 1995-01-20 | 2002-04-15 | Wakamoto Pharma Co Ltd | Entzündungshemmende augentropfen |
| GB9616208D0 (en) * | 1996-08-01 | 1996-09-11 | Smithkline Beecham Plc | Novel Compounds |
| US6218428B1 (en) | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
| US6872705B2 (en) | 2001-07-13 | 2005-03-29 | Allergan, Inc. | Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions |
| US20050234018A1 (en) * | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| DE102005046769A1 (de) * | 2005-09-29 | 2007-04-05 | Berlin-Chemie Ag | Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus) |
| WO2009006130A2 (en) | 2007-06-28 | 2009-01-08 | Bausch & Lomb Incorporated | Salt free hyaluronate ophthalmic solution |
| JP2012520880A (ja) * | 2009-03-17 | 2012-09-10 | アーシエックス セラピューティックス， インコーポレイテッド | ケトチフェンの眼科用製剤および使用方法 |
| EP2440185B1 (en) | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| US20130165419A1 (en) | 2011-12-21 | 2013-06-27 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| CN102973925A (zh) * | 2012-11-27 | 2013-03-20 | 顾月燕 | 一种促进伤口愈合的组合物的制备方法 |
| CA2933065C (en) * | 2013-12-12 | 2021-08-24 | Innovation Technologies, Inc. | Materials and methods for controlling infections |
| US10610499B2 (en) | 2016-05-06 | 2020-04-07 | SaCSh Corp. | Ophthalmic compositions |
-
2017
- 2017-05-05 US US15/587,764 patent/US10610499B2/en active Active
- 2017-05-05 TW TW106114962A patent/TWI738774B/zh active
- 2017-05-05 BR BR122024001664-8A patent/BR122024001664A2/pt not_active Application Discontinuation
- 2017-05-05 EP EP17723886.2A patent/EP3452093B1/en active Active
- 2017-05-05 JP JP2019510569A patent/JP6941157B2/ja active Active
- 2017-05-05 WO PCT/US2017/031211 patent/WO2017192944A1/en not_active Ceased
- 2017-05-05 AU AU2017261303A patent/AU2017261303B9/en active Active
- 2017-05-05 DK DK17723886.2T patent/DK3452093T3/da active
- 2017-05-05 CN CN201780041866.9A patent/CN109715215A/zh active Pending
- 2017-05-05 CA CA3022983A patent/CA3022983C/en active Active
-
2018
- 2018-01-24 US US15/878,767 patent/US10632083B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3022983A1 (en) | 2017-11-09 |
| TWI738774B (zh) | 2021-09-11 |
| AU2017261303A1 (en) | 2018-11-22 |
| BR112018072647A2 (pt) | 2019-02-19 |
| JP6941157B2 (ja) | 2021-09-29 |
| US10610499B2 (en) | 2020-04-07 |
| WO2017192944A1 (en) | 2017-11-09 |
| CN109715215A (zh) | 2019-05-03 |
| EP3452093B1 (en) | 2021-04-28 |
| US20170319515A1 (en) | 2017-11-09 |
| BR122024001664A2 (pt) | 2024-02-27 |
| AU2017261303B9 (en) | 2021-09-23 |
| US10632083B2 (en) | 2020-04-28 |
| JP2019515040A (ja) | 2019-06-06 |
| EP3452093A1 (en) | 2019-03-13 |
| US20180147162A1 (en) | 2018-05-31 |
| DK3452093T3 (da) | 2021-06-28 |
| AU2017261303B2 (en) | 2021-09-16 |
| TW201740928A (zh) | 2017-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10632083B2 (en) | Ophthalmic compositions | |
| TWI677343B (zh) | 含有普維酮-碘之眼用組成物 | |
| TW201717973A (zh) | 無刺激性眼用聚乙烯吡咯啶酮-碘組成物 | |
| EP3986377A1 (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis | |
| US20220071924A1 (en) | Treatment of ocular diseases with ophthalmic tapinarof compositions | |
| BR112018072647B1 (pt) | Composições oftálmicas | |
| US20210290527A1 (en) | Compositions and Methods for Treatment of Ocular Conditions | |
| HK1130665A (en) | Ophthalmic compositions comprising povidone-iodine | |
| HK1192720B (en) | Ophthalmic compositions comprising providone-iodine | |
| HK1192720A (zh) | 包含聚维酮碘的眼用组合物 | |
| HK1130665B (en) | Ophthalmic compositions comprising povidone-iodine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220427 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241225 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241225 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241225 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260310 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260310 |